Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in San Giovanni Rotondo – page 12

159 clinical trials in San Giovanni Rotondo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
San Giovanni Rotondo at a glance
159
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

159 trials in San Giovanni Rotondo

Open in trial search

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Huntington's disease

Not recruiting

Study on the Safety and Effects of PTC518 for Patients with Huntington's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:PTC518
  • Sponsor:PTC Therapeutics Inc.

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Prostate cancer metastatic

Not recruiting

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Colorectal cancer metastatic

Not recruiting

Study on Retreatment with Encorafenib and Cetuximab for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Fondazione GONO G.I.

Epstein-Barr virus associated lymphoma

Not recruiting

Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ganciclovir Sodium
  • Sponsor:Viracta Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in San Giovanni Rotondo

What the registry says about research in the country

01 Gastrointestinal Oncology

Clinical research focusing on metastatic colorectal cancer and gastroesophageal cancers, evaluating novel combination therapies and targeted treatments.

  • Advanced colorectal cancer treatments
  • HER2-positive gastric cancer therapies
  • Targeted molecular therapies
02 Inflammatory Bowel Disease

Studies examining innovative treatments for Crohn's Disease and Ulcerative Colitis, testing new therapeutic combinations and treatment strategies.

  • Novel biological therapies
  • Combination treatment approaches
  • Disease remission strategies
03 Hematologic Malignancies

Research initiatives in acute myeloid leukemia, multiple myeloma, and other blood cancers, exploring innovative therapeutic approaches.

  • Targeted leukemia treatments
  • Novel drug combinations
  • Immunotherapy approaches
04 Breast and Urological Cancers

Investigations into early breast cancer treatments and therapies for prostate cancer, with focus on hormone-responsive diseases.

  • Endocrine therapy optimization
  • Advanced prostate cancer treatments
  • Targeted therapeutic approaches
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.